SoftOx Solutions AS announced that the Danish Medicines Agency approved the Phase 1 clinical trials for SoftOx Inhaled Solution, an aerosolized antimicrobial product intended for the treatment of upper respiratory tract infections and lower respiratory tract infections. SIS is a stabilised solution of hypochlorous acid that can be aerosolised and inhaled. The antimicrobial properties of hypochlorous acid are well described, and endogenous production of hypochlorous acid is one of the key elements involved in host immunity from infectious disease. SIS-01 is a single-centre, randomised, double-blind, placebo-controlled study, the study will explore the safety and tolerability of single and multiples doses of inhaled nebulised SIS in healthy subjects.